Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5581902 | Clinical Lymphoma Myeloma and Leukemia | 2017 | 20 Pages |
Abstract
Overall, despite the older age and a greater number of patients with high-risk category (including Philadelphia chromosome-positive) in the hyper-CVAD group, this did not translate into a difference in survival outcome between the 2 groups. The hyper-CVAD regimen appears to be feasible for adult patients with ALL in terms of tolerability and efficacy.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Jean El-Cheikh, Imane El Dika, Radwan Massoud, Maya Charafeddine, Rami Mahfouz, Mohamed A. Kharfan-Dabaja, Ali Bazarbachi,